Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH

• Published in: BMC gastroenterology 2019-12, Vol.19 (1), p.228-228, Article 228
• Main Authors: Baandrup Kristiansen, Maria Nicoline, Veidal, Sanne Skovgård, Christoffersen, Christina, Feigh, Michael, Vrang, Niels, Roth, Jonathan David, Erickson, Mary, Adorini, Luciano, Jelsing, Jacob
• Format: Article
• Language: English
• Subjects: Amylin; Animal models; Animals; Bile Acids and Salts - therapeutic use; Biopsy; Body Weight - drug effects; Chalcones - therapeutic use; Clinical trials; Collagen; Collagen (type I); Collagen Type I - analysis; Diet; Diet, High-Fat; Disease model; Drug dosages; FDA approval; Fibrosis; Galectin 3 - analysis; Galectin-3; Gastroenterology; Histochemistry; Immunohistochemistry; Islet Amyloid Polypeptide - administration & dosage; Laboratory animals; Leptin; Leptin - deficiency; Lipids; Lipids - analysis; Liraglutide; Liraglutide - therapeutic use; Liver; Liver - chemistry; Liver - drug effects; Liver - pathology; Liver biopsy; Liver Cirrhosis - pathology; Liver diseases; Liver morphometry; Male; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - pathology; Nonalcoholic steatohepatitis; Obesity; Obesity - complications; Obeticholic acid; Organ Size - drug effects; Pharmacodynamics; PPAR alpha - agonists; PPAR delta - agonists; Propionates - therapeutic use; Reproducibility of Results; Software; Statistical analysis; Stereology; Variance analysis
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-019-1149-z

Compounds in clinical development for nonalcoholic steatohepatitis (NASH) improve liver histopathology in diet-induced obese mouse models of biopsy-confirmed NASH. Since the biopsy section used for histopathological evaluation represents only